Cumulative incidence remains highest for Kaposi sarcoma, non-Hodgkin lymphoma, and lung cancer, but rates of anal, colorectal, and liver cancers are increasing.
Now that antiretroviral therapy (ART) has prolonged the lives of HIV-infected patients, various cancers have become increasingly common. However, whether this effect stems from longer lifespan or represents a true increase in incidence remains uncertain. In HIV-infected people, cancer risk may be increased because of impaired immune function and chronic inflammation or the presence of risk factors such as viral coinfections or smoking.
In a study involving 16 NA-ACCORD cohorts from the U.S. and Canada, investigators compared trends in cumulative incidence of nine cancers (lung, anal, colorectal, liver, and oropharyngeal cancers, Kaposi sarcoma [KS], non-Hodgkin lymphoma [NHL], Hodgkin disease [HL], and melanoma) between 86,620 HIV-infected a…
Reviewing Author
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)